A study in British Journal of Dermatology identified TET2 gene loss as a key driver of melanoma aggressiveness. Loss of TET2 and 5-hydroxymethylcytosine enhances PGC1α expression and oxidative phosphorylation activity, promoting tumor growth and therapy resistance. Interestingly, tumors with this pathway activation show vulnerability to oxidative phosphorylation inhibition, opening doors to personalized melanoma therapies . To read more click here ##Reference## Fischer GM, et al. Loss of TET2 facilitates aggressive behavior in cutaneous melanoma by inducing PGC1α/oxidative phosphorylation (OXPHOS).
Br J Dermatol. 2025 Oct;193(4):693–707. doi:10.1093/bjd/ljaf378.## Which mechanism led to a more aggressive melanoma phenotype in recent studies? a) TET2/5-hmC loss activating PGC1α b) KRAS amplification c) p53 overexpression d) Decreased MAPK activity
